8-K: Catheter Precision Extends $1.5M Related-Party Debt

Catheter Precision, Inc. has amended its 8% Short Term Promissory Notes, totaling $1.5 million, extending their maturity dates to 2028 and 2029.

Summary

• Catheter Precision, Inc. (VTAK) amended its outstanding 8% Short Term Promissory Notes on December 31, 2025.
• The amendments extended the maturity dates of notes totaling $1.5 million, which were previously due on January 31, 2026.
• Notes held by David A. Jenkins (Executive Chair and CEO) for $500,000 and FatBoy Capital, L.P. (an affiliate of Mr. Jenkins) for $500,000 (comprising three notes of $150,000, $250,000, and $100,000) now mature on January 31, 2029.
• A note held by Jenkins Family Charitable Institute (an affiliate of Mr. Jenkins) for $500,000 now matures on January 31, 2028.
• David A. Jenkins is the Executive Chair and Chief Executive Officer, managing member of the general partner of FatBoy Capital, L.P., and was the Settlor and Initial Trustee of Jenkins Family Charitable Institute. His adult daughter is the current Trustee of the Institute and serves as the company's non-executive chief operating officer.
• Mr. Jenkins and his affiliates also own stock options and rights to receive royalties equal to an aggregate 11.77% of net sales of the LockeT device.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative. While the debt extension provides temporary relief, the reliance on related-party financing and the need for repeated extensions suggest underlying financial challenges and a lack of independent capital access, which are significant concerns for investors.

Positives

• The extension of maturity dates provides Catheter Precision with additional time to repay its short-term debt obligations, potentially easing immediate liquidity pressures.
• The continued support from key insiders (David A. Jenkins and his affiliates) through debt extensions indicates their ongoing commitment to the company.

Negatives

• The repeated extension of short-term promissory notes, particularly from related parties, suggests ongoing financial strain and potential difficulty in generating sufficient cash flow or securing alternative financing.
• Reliance on related-party debt can raise concerns about the company's ability to access capital from independent sources and potential conflicts of interest.
• The notes carry an 8% interest rate, which represents a cost of capital that will continue to accrue over the extended periods.

Risks

• The notes have not been registered under the Securities Act of 1933 or state securities laws, and were issued for investment purposes, not resale, limiting their transferability.
• Holders of these notes are subject to restrictions on transferability and resale and may be required to bear the financial risks of this investment for an indefinite period.
• Investing and/or re-investing in these notes involves a high degree of risk, and holders should not invest unless they can afford to lose their entire investment.
• The company's continued reliance on related-party financing may indicate underlying operational or financial challenges that could impact future performance and shareholder value.

Future Outlook

The extension of these promissory notes defers the company's immediate debt repayment obligations, providing additional time to manage its financial position. This implies a continued need for operational funding or future capital generation to meet these obligations by the new maturity dates in 2028 and 2029.

Management Comments

• Philip Anderson, Chief Financial Officer, signed the report on behalf of Catheter Precision, Inc.
• David A. Jenkins, Managing Member of SEACAP MANAGEMENT, LLC (General Partner of FatBoy Capital, L.P.), signed the amendment for FatBoy Capital, L.P.
• David A. Jenkins also signed the amendment for his individual note.
• Casey Jenkins, Trustee, signed the amendment for Jenkins Family Charitable Institute.

Industry Context

In the medical device industry, particularly for development-stage companies, securing financing is crucial. While debt extensions can provide necessary breathing room, repeated reliance on related-party debt, as seen here, can signal challenges in attracting external, arms-length financing. This situation suggests the company may be facing liquidity constraints or slower-than-expected revenue generation, which is not uncommon for companies in the development phase but warrants close monitoring.

Comparison to Industry Standards

• Companies with strong financial health typically have access to diverse funding sources, including institutional lenders or public markets, for their debt needs. The repeated extension of related-party short-term debt, rather than refinancing with independent third parties, deviates from the standard practice of mature, financially robust companies.
• For early-stage medical device companies, some reliance on insider funding is common. However, the pattern of extending short-term notes rather than converting them to equity or securing longer-term, more conventional debt could indicate a lack of significant progress towards profitability or market acceptance that would attract broader investor interest.
• Unlike peers that might announce new product launches, significant clinical trial milestones, or substantial revenue growth to support their financial obligations, this filing primarily addresses debt management, suggesting a focus on maintaining financial stability rather than growth-driven capital deployment.

Corporate Governance

Related Party Transactions

• David A. Jenkins, the Executive Chair and Chief Executive Officer, is the holder of a $500,000 promissory note.
• Mr. Jenkins is the managing member of the general partner of FatBoy Capital, L.P., which holds $500,000 in promissory notes.
• Mr. Jenkins was the Settlor and Initial Trustee of Jenkins Family Charitable Institute, which holds a $500,000 promissory note. His adult daughter is the current Trustee.
• Mr. Jenkins and his affiliates own stock options and rights to receive royalties equal to an aggregate 11.77% of net sales of the LockeT device.
• Missiaen Huck, Mr. Jenkins' adult daughter, serves as the company's non-executive chief operating officer.

Stakeholder Impact

• Shareholders: Face increased risk due to the company's continued reliance on related-party debt and the implied liquidity challenges, which could impact future share performance and dilution if equity financing becomes necessary.
• Creditors (Note Holders): Have their repayment deferred, extending their investment horizon and exposure to the company's financial health.
• Management: The Executive Chair and CEO, David A. Jenkins, and his family affiliates remain significant creditors, aligning their interests with the company's long-term viability but also highlighting potential conflicts of interest.

Next Steps

• Catheter Precision, Inc. will need to manage its operations and cash flow to meet the new debt maturity dates of January 31, 2028, and January 31, 2029.
• The company may explore further financing options, including additional debt or equity raises, to address its long-term capital needs.

Key Dates

Recommendation

The repeated extension of short-term promissory notes, particularly from related parties, signals ongoing financial distress and a likely inability to secure conventional financing. This pattern suggests persistent liquidity challenges and a lack of operational cash flow to meet obligations. While the extensions provide temporary relief, they do not address the fundamental issues and increase the risk profile for public shareholders, making the stock a 'sell' for a seasoned investor.

Keywords

Promissory Notes, Debt Extension, Related Party Transactions, Short Term Debt, Corporate Finance, SEC Filing, Catheter Precision, VTAK, Liquidity, Financial Risk